These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32982259)

  • 1. Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease.
    Cernaro V; Calimeri S; Laudani A; Santoro D
    Ther Clin Risk Manag; 2020; 16():871-880. PubMed ID: 32982259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
    Cernaro V; Santoro D; Lacquaniti A; Costantino G; Visconti L; Buemi A; Buemi M
    Int J Nephrol Renovasc Dis; 2016; 9():11-9. PubMed ID: 26893577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperphosphataemia: treatment options.
    Malberti F
    Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Negi S; Shigematsu T
    Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure.
    Spaia S
    Hippokratia; 2011 Jan; 15(Suppl 1):22-6. PubMed ID: 21897754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperphosphatemia and phosphate binders.
    Schucker JJ; Ward KE
    Am J Health Syst Pharm; 2005 Nov; 62(22):2355-61. PubMed ID: 16278327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of the phosphate binder, lanthanum carbonate.
    Damment SJ
    Ren Fail; 2011; 33(2):217-24. PubMed ID: 21332344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment.
    Coppolino G; Lucisano S; Rivoli L; Fuiano G; Villari A; Villari I; Leonello G; Lacquaniti A; Santoro D; Buemi M
    Ther Apher Dial; 2015 Oct; 19(5):471-6. PubMed ID: 25866250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.
    Damment SJ; Pennick M
    Clin Pharmacokinet; 2008; 47(9):553-63. PubMed ID: 18698878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
    Frazão JM; Adragão T
    Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
    Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC
    Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.